Daiichi Sankyo Co. Ltd.'s Fiscal Year is From April To March.
The item "Enterprise-Value-To-Ebitda-Ratio" stands at 14.48 as of 06/30/2025, the lowest value at least since 03/31/2022, the period currently displayed.
As of the end of Daiichi Sankyo Co. Ltd.'s first quarter, the item "Enterprise Value To Ebitda Ratio" stands at 14.48. This represents a decrease of -10.27 percent compared to it's value at the end of it's fourth quarter of the company's last fiscal year.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -49.23 percent compared to the value the year prior.
The 1 year change in percent is -49.23.
The 3 year change in percent is -68.66.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Enterprise Value To Ebitda Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Enterprise Value To Ebitda Ratio | 486,508,953,600.00 |
![]() | AbbVie Inc - Enterprise Value To Ebitda Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Enterprise Value To Ebitda Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Enterprise Value To Ebitda Ratio | 280,205,508,085.11 |